Approval summary for imatinib mesylate capsules in the treatment of chronic Myelogenous Leukemia

Clinical Cancer Research

Volumn 8, Issue 5, 2002, Pages 935-942

  Cohen, Martin H ^a   Williams, Grant ^a   Johnson, John R ^a   Duan, John ^a   Gobburu, Jogarao ^a   Rahman, Atiqur ^a   Benson, Kimberly ^a   Leighton, John ^a   Kim, Sung K ^a   Wood, Rebecca ^a   Rothmann, Mark ^a   Chen, Gang ^a   Maung U, Khin ^a   Staten, Ann M ^a   Pazdur, Richard ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GENE PRODUCT; IMATINIB;

ABDOMINAL PAIN; ADULT; AGED; ARTHRALGIA; ARTICLE; BIOAVAILABILITY; CELL DIVISION; CHRONIC MYELOID LEUKEMIA; DIARRHEA; DRUG APPROVAL; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DYSPEPSIA; EPISTAXIS; FATIGUE; FEMALE; FEVER; HUMAN; MAJOR CLINICAL STUDY; MALE; MALIGNANT TRANSFORMATION; PRIORITY JOURNAL; RASH;

ANTINEOPLASTIC AGENTS; CAPSULES; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; DIARRHEA; DRUG APPROVAL; EXANTHEMA; HEADACHE; LEUKEMIA, MYELOID, CHRONIC; NAUSEA; PIPERAZINES; PYRIMIDINES; TREATMENT OUTCOME; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION; VOMITING;

EID: 0036094117     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Chronic myelocytic leukemia: Clonal origin in a stem cell common to the granulocyte, erythrocyte, platelet, and monocyte/macrophage
2. Clonal origin of chronic myelocytic leukemia in man
3. An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: Developed for the American Society of Hematology
4. Treatment of chronic myelogenous leukemia in accelerated and blastic phases with daunorubicin, high-dose cytarabine, and granulocyte-macrophage colony-stimulating factor
5. Targeting the BCR-ABL tyrosine kinase in chronic myeloid leukemia
6. The biology of chronic myeloid leukemia
7. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome
8. Tyrosine kinase activity and transformation potency of bcr-abl onco-gene products
9. The BCR gene and Philadelphia chromosome-positive leukemogenesis
10. Chronic myelogenous leukemia
11. Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia
12. The molecular biology of chronic myeloid leukemia
13. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor
14. Expression of Xk1-1, a Xenopus gene related to mammalian c-kit, in dorsal embryonic tissue
15. Early nonspecific immune responses and immunity to blood-stage nonlethal Plasmodium yoelii malaria
16. The expression pattern of the c-kit ligand in gonads of mice supports a role for the c-kit receptor in oocyte growth and in proliferation of spermatogonia
17. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia
18. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification
19. Chronic myelogenous leukemia in blast crisis. Analysis of 242 patients
20. Treatment of chronic myelogenous leukemia: Current status and investigational options
21. UK Medical Research Council randomised, multicentre trial of IFN-α n1 for chronic myeloid leukaemia: Improved survival irrespective of cyto-genetic response
22. Randomized study on hydroxyurea alone versus hydroxyurea combined with low dose interferon-α 2b for chronic myeloid leukemia
23. Interferon-α 2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia
24. Randomized comparison of interferon-α with busulfan and hydroxyurea in chronic myelogenous leukemia
25. Interferon α-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukaemia
26. A randomized trial comparing interferon-α with busulfan for newly diagnosed chronic myelogenous leukemia in chronic phase